Clinical trial · Observational
Assesment of Upper Egypt Experience in Autologous Bone Marrow Transplantation of Patients With Hematological Malignancies: A Cohor Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260926-000001
Summary
Brief summary (as posted)
Autologous hematopoietic stem cell transplantation (ASCT) is an important treatment for eligible patients with hematological malignancies, particularly multiple myeloma and relapsed lymphoma. Although advances in transplantation have improved outcomes, complications such as infections, febrile neutropenia, mucositis, delayed engraftment, organ toxicity, and relapse remain significant. This study aims to evaluate clinical outcomes and patient satisfaction after ASCT and identify factors associated with favorable or unfavorable transplant outcomes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Marrow Transplant Complications | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Autologous bone marrow transplant patients
Primary outcomes (1)
- measure
- PFS
- timeFrame
- through study completion, an average of 2 year
- description
- Clinical outcome of autologous hematopoietic stem cell transplantation, including overall survival (OS) and Progression-Free Survival (PFS).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients (≥18 years) with a confirmed diagnosis of a hematological malignancy. * Patients undergoing their autologous hematopoietic stem cell transplantation (ASCT). * willingness to participate in the study Exclusion Criteria: * Patients undergoing allogeneic hematopoietic stem cell transplantation. * Patients with uncontrolled active infection or severe organ dysfunction that contraindicates transplantation. * Patients with incomplete clinical data or who withdraw consent during the study period.
References
Publications (0)
Data not yet available